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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S188Background: Cryopreserved cord blood units (CBU) provide
a source of donor hematopoietic stem cells for trans-
plantation for patients in need of a suitable donor. Primary
graft failures and delayed engraftment occur in up to
10-15% of patients following cord blood (CB) transplant
which may be due to low potency, deﬁned as low levels of
viable engrafting hematopoietic stem and progenitor cells.
The majority of transplant centers currently select CBUs for
their patients based on HLA match, pre-cryopreservation
total nucleated cell count, and, in some centers, viable
CD34+ content. These methods do not account for potential
insults caused by cryopreservation and thawing which may
impact the overall potency. We and others have shown that
post-thaw hematopoietic colony forming units (CFU)
measured on the transplanted product reﬂect potency and
predict engraftment and survival. However, post-thaw CFUs
are not available at the time of CBU selection or trans-
plantation because results are not available for 14 days.
CFUs measured on fresh CB correlate with the number of
cells expressing high levels of the enzyme aldehyde dehy-
drogenase (ALDHbr), suggesting that ALDHbr content could
be a biomarker for potency. To test this, we retrospectively
compared ALDHbrcontent of segments associated with
transplanted CBUs and ALDHbrper kilogram correlated
with engraftment. Therefore, we developed a rapid ALDH-
based potency assay in CBU attached segments that could
be performed when HLA conﬁrmatory typing (CT) was
requested.
Methods: CBUs with attached segments banked at the Car-
olinas Cord Blood Bank and requested for CT between March
2010 and August 2013 were analyzed (n¼2766). Each
segment was thawed and an aliquot of CB was taken for HLA
CT. The remaining CB was washed with 5% dextran/albumin
to remove the DMSO. Samples of 20,000 nucleated cells were
plated in quadruplicate to quantitate CFUs. The number of
viable (7-AAD-), CD45+, ALDHbr, and CD34+ nucleated cells
(glycophorin A-) were measured by ﬂow cytometry using
multiparameter gating.
Results: The number of ALDHbr (Spearman Correlation,
r¼0.81) and [ALDHbr viable CD34+] cells (r¼0.73) both
correlated well with CFUs measured on the segment
(n¼2730 for both analyses). In contrast, CFU correlated less
well with viable CD34+(n¼2727, r¼0.30). These correlations
were valid regardless of time in cryostorage. Of the more
than 2700 units assayed, more than 800 have been admin-
istered to patients. Thus, transplant outcomes data will be
available to compare with laboratory metrics.
Conclusion: We developed a segment-based potency assay
for CBUs selected for CT in a public CB bank. Expression of
ALDH alone and in combination with viable CD34+ best
identiﬁed CBUs with high CFUs content and has potential forTable 1
Case # Age, Sex 1 2 yrs, F 2 6 yrs, M
Reason for SCT BLS 2; MDS
Conditioning Bu/Cy/ ATG Bu/Cy
Stem cell source BM PBSC
%wt gain at onset of SOS 40 9
Bili/Creatinine at initiation of CVVH (mg/dl) 14/3.1 2.3/1.6
SOS onset post SCT (days) 10 6
Mechanical ventilation (MV) or O2 support MV MV
CVVH duration (days) 0.5 5
CVVH ﬁlter M60 M60
CVVH anticoagulation Heparin Citrate
Duration without clot (days) 0.5 3
Deﬁbrotide No No
Outcome Died (day 1) CR*
BLS II e bare lymphocyte syndrome type II
* CR ¼ US liver and serum bilirubin returned to normal;use as a biomarker of potency. Viable CD34+ alone was not
predictive of potency. Further analyses correlating these re-
sults with engraftment are in progress.SUPPORTIVE CARE
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Introduction: SOS, a syndrome characterized by hepatic si-
nusoidal obstruction, is a frequent cause of acute kidney
injury (AKI) following SCT. In this setting, mortality rates are
>90% despite aggressive therapy. While deﬁbrotide has
emerged as a therapeutic option for many patients with SOS,
managing ﬂuid overload (FO) and electrolyte and acid base
balance in the context of AKI remains a signiﬁcant challenge.
Objective: We retrospectively reviewed our effort to stan-
dardize our approach in patients with AKI and FO due to SOS
following SCT.
Methods: From 9/11 to 9/13, 44 SCT were performed. Six
(13.6%) developed AKI and FO related to SOS. All patients
were treated with ﬂuid/sodium restriction and diuretics
prior to initiation of CVVH. Early indications for CVVH
included diuretic-resistant FO >5% and oligo/anuric AKI. We
performed 57 CVVH procedures (procedure ¼ 24 hours)
with pre and post dilution using citrate or heparin
anticoagulation.
Results: (Table 1) Four of six patients (66%) had complete
recovery (CR) of SOS symptoms (mean recovery time 5 days).
CVVH was initiated within 16 hrs after diagnosis of FO or
oligo/anuric AKI. Mean time on CVVH was 9 days. The me-
dian patency of the CVVH tubing set was 3.5 days. Deﬁbro-
tide was used in 50% of patients. Citrate anticoagulation was3 16 yrs, M 4 12 yrs, F 5 17 yrs, M 6 15 yrs, M
CML AML MDS AML
Bu/Cy/ ATG Bu/Cy/ ATG Bu/Cy/ ATG Bu/Cy/ ATG
D-UCB BM PBSC BM
5 10 20 10
12/3.6 2.6/1.1 2.1/1.0 1.9/2.4
7 11 19 20
O2 O2 MV MV
9 15 16 12
M60/M100 M60 M100 M100
Citrate Citrate Citrate/ Heparin Citrate/ Heparin
4 5 4 6
Yes Yes Yes No
CR CR Died (day 21) CR
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S189used in 5 of 6 patients, and was well tolerated. Only 1 of 5
developed citrate gap, which resolved after adjusting citrate
rate. No serious hemorrhagic events were observed. Two of 6
patients died (34%) e Case #1 due to SOS, and #5 due to
systemic CMV infection. These corresponded to the patients
with the highest FO.
Conclusions: 1. Early initiation of CVVH may be a useful
modality to prevent progressive ﬂuid overload and maintain
electrolyte and acid base balance in patients with FO and AKI
following SOS.
2. CVVH with citrate regional anticoagulation is safe and
well tolerated in patients with SOS.SCT Type PRA
(percentage)
Indication for
Treatment
Patient 1 Double umbilical
cord
13 Refractory
thrombocytopenia
without bleed
Patient 2 8/8 HLA matched
peripheral
84 Refractory
thrombocytopenia
with oropharyngeal
bleeding
Patient 3 Double umbilical
cord
100 a. Refractory
thrombocytopenia
with fever
b. Refractory
thrombocytopenia
with GI bleed279
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Background: Transplant-associated thrombotic micro-
angiopathy (TA-TMA) is a signiﬁcant complication of he-
matopoietic stem cell transplantation and poses a challenge
with diagnosis and management.
Objectives: To report a case of TA-TMA in an allogeneic bone
marrow transplant (BMT) patient and discuss diagnostic and
management challenges.
Design/Method: Case Report.
Results: Seven year old female with B-thalassemia major
who underwent 10/10 matched unrelated donor BMT. Her
conditioning regimen included Busulfan, Fludarabine,
Cyclophosphamide and ATG, graft versus host disease
(GVHD) prophylaxis included cyclosporin and short course
methotrexate. Post-transplant course was complicated by
grade II acute GVHD, intracranial bleed, GI hemorrhage and
pericardial effusion. She developed several episodes of acute
kidney injury post-transplant with recovery of renal function
back to baseline creatinine (0.3-0.5 mg/dL). Six months post
transplant the patient developed hematuria and worsening
proteinuria followed by intractable hypertension. Renal
function gradually worsened with creatinine rising to w1.6
mg/dL and ended up with oliguria and ﬂuid overload. In
addition she developed hemolytic anemia, thrombocyto-
penia and peripheral blood schistocytes. Several measures
were attempted to improve her renal function including
stopping her calcineurin inhibitor, decreasing her diuretic
regimen and stopping ACE inhibition. Renal biopsy was ob-
tained and showed acute, severe thrombotic micro-
angiopathy. Complement serologies (C3, C4, CFI, CFH levels
and CFH autoantibody) were all normal or elevated. Hemo-
dialysis, therapeutic plasma exchange and basiliximab were
initiated. She received 2 doses of basiliximab and 10 treat-
ments of plasma exchange, resulting in no response. The
patient continued on thrice weekly dialysis. The patient
tolerated dialysis with great difﬁculty complicated by bilat-
eral eye pain, dizziness, extremity tingling and abdominal
pain during her treatments. Finally the patient developed a
syncopal event with mental status changes following one ofher dialysis episodes. EEG conﬁrmed seizure activity. Brain
MRI showed diffuse white matter abnormality consistent
with severe TMA. Given the patient’s progressive worsening
and extreme symptoms, Eculizumab was started. After 3
doses, she has begun to show signs of hematologic recovery
with no signs of renal recovery. Her blood pressure remains
very difﬁcult to control.
Conclusion: TA-TMA is an uncommon but signiﬁcant
complication of HSCT that presents signiﬁcant diagnostic
and management challenges. Even with accurate diagnosis
(clinically and histologically), optimal treatment strategies
remain elusive and the prognosis is poor.
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Introduction: Patients undergoing stem cell transplant
(SCT) for treatment of hematologic malignancies have often
been exposed to many blood products and may be allo-
immunized. This makes platelet transfusions less effective,
which is problematic in patients who are expected to be
profoundly thrombocytopenic for 3-4 weeks. A second-line
intervention in patients with refractory immune thrombo-
cytopenia is continuous intravenous immune globulin (IVIG)
at doses of 1 g/kg/day for 2 days and continuous platelet
transfusion (1 pack of platelets/hour for 72 hours). This
intervention has not been studied in allo-immunized SCT
patients.
Methods: A retrospective chart review was performed at the
University of Wisconsin Hospital to assess outcomes of the
continuous IVIG and platelet regimen in allo-immunized SCT
patients from 1/1/2009 to 12/31/2012. All patients also
received concurrent aminocaproic acid. Data points collected
include primary hematologic diagnosis, indication for treat-
ment, platelet response, clinical bleeding events, requirement
for further therapy, other complications during hospital stay,
and in-hospital mortality.
Results: All of the patients had an increase in platelet count
and therewere no new bleeding events during the treatment
period. The regimen does not appear to provide any long-
standing improvement in platelet response.
Discussion: Continuous IVIG and platelet transfusion does
not appear to decrease allo-reactivity as had been hoped for.
However, it does appear to be safe and does provide a
